Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia

Experimental Neurology

Volumn 150, Issue 2, 1998, Pages 235-239

  Heffernan, Josephine M ^a   Eastwood, Sharon L ^a   Nagy, Zsuzsanna ^a   Sanders, Maurice W ^b   McDonald, Brendan ^a   Harrison, Paul J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cerebral cortex; Gene expression; Neurodegenerative disorder; Synapse; Synaptic protein

Indexed keywords

MESSENGER RNA; POLYADENYLATED RNA; SYNAPTOPHYSIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; NEOCORTEX; OCCIPITAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPORAL CORTEX;

EID: 0032051614     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6772     Document Type: Article

References (31)

1. Beach T. G., McGeer E. G. Cholinergic fiber loss occurs in the absence of synaptophysin depletion in Alzheimer's disease primary visual cortex. Neurosci. Lett. 142:1992;253-256.
2. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82:1991;239-259.
3. Dickson D. S., Crystal H. A., Bevona C., Honer W., Vincent I., Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging. 16:1995;285-304.
4. Eastwood S. L., Burnet P. W. J., McDonald B., Clinton J., Harrison P. J. Synaptophysin gene expression in human brain: a quantitativein situ. Neuroscience. 59:1994;881-892.
5. Eastwood S. L., Burnet P. W. JP. W., Harrison P. J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 66:1995;309-319.
6. Folstein M. F., Folstein S. E., McHugh P. R. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr.Res. 12:1975;189-198.
7. Gabriel S. M., Haroutunian V., Powchik P., Honer W. G., Davidson M., Davies P., Davis K. L. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch. Gen. Psychiatry. 54:1997;559-566.
8. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J. H., Petersen R. C., Parisi J. E., Hyman B. T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:1997;17-24.
9. Harrison P. J. In vitro. Neurobiology and Psychiatry. 1995;Cambridge Univ. Press, Cambridge. p. 157-174.
10. Harrison P. J., Barton A. J. L., Najlerahim A., McDonald B., Pearson R. C. A. Regional and neuronal reductions of polyadenylated mRNA in Alzheimer's disease. Psychol. Med. 21:1991a;855-866.
11. Harrison P. J., Barton A. J. L., Najlerahim A, McDonald B., Pearson R. C. A. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated byin situ. Mol. Brain Res. 9:1991b;15-21.
12. s. Mol. Brain Res. 10:1991c;71-81.
13. Harrison P. J., Heath P. R., Eastwood S. L., Burnet P. W. J., McDonald B., Pearson R. C. A. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: Selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 200:1995;151-154.
14. Harrison P. J., Burnet P. W. J., Falkai P., Bogerts B., Eastwood S. L. Gene expression and neuronal activity in schizophrenia: A study of polyadenylated mRNA in the hippocampal formation and cerebral cortex. Schizophr. Res. 26:1997;93-102.
15. Honer W. G., Dickson D. S., Gleeson J., Davies P. Regional synaptic pathology in Alzheimer's disease. Neurobiol. Aging. 13:1992;375-382.
16. Kingsbury A. E., Foster O. J. F., Nisbet A. P., Cairns N., Bray L., Eve D. J., Lees A. J., Marsden C. D. Tissue pH as an indicator of mRNA preservation in human brain post-mortem. Mol. Brain Res. 28:1995;311-318.
17. Lassmann H., Weiler R., Fischer R., Bancher C., Jellinger K., Floor E., Danielczyk W., Seitelberger F., Winkler H. Synaptic pathology in Alzheimer's disease: Immunological data for markers of synaptic and large dense-core vesicles. Neuroscience. 46:1992;1-8.
18. Lukiw W. J., St.George-Hyslop P., McLachlan D. R. Chromatin structure, gene expression, and nuclear aluminum in Alzheimer's disease. Harrison P. J. Regulation of Gene Expression and Brain Function. 1994;31-45 Springer, Berlin.
19. Mann D. M. A. Pyramidal nerve cell loss in Alzheimer's disease. Neurodegeneration. 5:1996;423-427.
20. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol. Histopathol. 10:1995;509-519.
21. Masliah E., Terry R. D., De Teresa R., Hansen L. A. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 103:1989;234-239.
22. Masliah E., Terry R. D., Alford M., DeTeresa R., Hansen L. A. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am. J. Pathol. 138:1991;235-246.
23. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardisation of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
24. Nagy Zs, Esiri M. M., Jobst K. A., Morris J. H., King E. M-F., McDonald B., Litchfield S., Smith A., Barnetson L., Smith A. D. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia. 6:1995;21-31.
25. Roth M., Huppert F., Tim E., Mountjoy C. Q. CAMDEX: The Cambridge Examination for Mental Disorders in the Elderly. 1988;Cambridge Univ. Press, Cambridge.
26. Samuel W., Alford M., Hofstetter C. R., Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J. Neuropathol. Exp. Neurol. 56:1997;499-508.
27. Scheff S. W., Price D. A. Synapse loss in the temporal lobe in Alzheimer's disease. Ann. Neurol. 33:1993;190-199.
28. Sze C-I., Tronosco J. C., Kawas C., Mouton P., Price D. L., Martin L. J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;933-944.
29. Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
30. Zhan S-S., Beyreuther K., Schmitt H. P. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia. 4:1993;66-74.
31. Zhan S-S., Beyreuther K., Schmitt H. P. Synaptophysin immunoreactivity of the cortical neuropil in vascular dementia of Binswanger type compared with the dementia of Alzheimer type and nondemented controls. Dementia. 5:1994;79-87.